• Acquisition of Amplia Therapeutics - Questions & Answers

    More +
  • CEO announces focus on Immuno-Oncology and Acquisition of 2 Cancer Drug Candidates

    More +
  • Contact Us

    Contact us for help, support or advice.

    More +

Welcome to Innate Immunotherapeutics

Innate Immunotherapeutics is an Australian medical biotechnology company advancing the development of drugs that inhibit Focal Adhesion Kinase (FAK). FAK is fast becoming an important target in hard to treat cancers where tumours use FAK to build a protective wall to shield against the onslaught of the immune system. FAK is also implicated in a number of chronic fibrotic diseases.

The Company has two FAK inhibiting drug candidates which are being initially positioned for clinical development targeting pancreatic cancer, high grade serous ovarian cancer, and idiopathic pulmonary fibrosis.